Amit Rakhit
Consultant / Advisor chez The New York City Investment Fund Manager, Inc.
Profil
Amit Rakhit is currently an Advisor at The New York City Investment Fund Manager, Inc. He previously held positions as the Chief Executive Officer at Sporos Bioventures, Inc., President & Chief Executive Officer at Flare Therapeutics, Inc., Director at Asylia Therapeutics, Inc., and Director at Stellanova Therapeutics, Inc. Prior to his roles in the biotech industry, he worked as the Vice President-Intercontinental Medical at Bristol Myers Squibb Co. from 2001 to 2011 and as the Senior Vice President at Biogen, Inc. from 2014 to 2016.
Dr. Rakhit also served as the President of Ovid Therapeutics, Inc. from 2019 to 2021.
He obtained his undergraduate degree from the University of California, Berkeley in 1991 and holds MBA degrees from both London Business School and Columbia Business School, which he earned in 2010.
Additionally, he received a graduate degree from Vanderbilt University School of Medicine in 2003 and a doctorate degree from Tufts University School of Medicine in 1995.
Postes actifs de Amit Rakhit
| Sociétés | Poste | Début |
|---|---|---|
The New York City Investment Fund Manager, Inc.
 The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Consultant / Advisor | - |
Anciens postes connus de Amit Rakhit
| Sociétés | Poste | Fin |
|---|---|---|
Stellanova Therapeutics, Inc.
 Stellanova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stellanova Therapeutics, Inc. is a private biotechnology company based in Houston, TX. The company is focused on developing therapies to treat cancers that are resistant to current treatments by targeting the tumor microenvironment. Stellanova's drug pipeline targets cancer-associated fibroblasts that spur tumors, which has shown unprecedented anti-tumor activity in multiple resistant cancer models. The company was founded by Rosa F. Hwang, Harold Levy, and Ronald A. DePinho, and the CEO is Emmanuelle Schuler. | Director/Board Member | 01/06/2022 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Director/Board Member | 01/06/2022 |
| OVID THERAPEUTICS INC. | President | 01/08/2021 |
| BIOGEN INC. | Corporate Officer/Principal | 01/03/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/06/2011 |
Formation de Amit Rakhit
| University of California, Berkeley | Undergraduate Degree |
| London Business School | Masters Business Admin |
| Columbia Business School | Masters Business Admin |
| Vanderbilt University School of Medicine | Graduate Degree |
| Tufts University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOGEN INC. | Health Technology |
| OVID THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
The New York City Investment Fund Manager, Inc.
The New York City Investment Fund Manager, Inc. Investment ManagersFinance The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States. | Finance |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Health Technology |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Health Technology |
Stellanova Therapeutics, Inc.
Stellanova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stellanova Therapeutics, Inc. is a private biotechnology company based in Houston, TX. The company is focused on developing therapies to treat cancers that are resistant to current treatments by targeting the tumor microenvironment. Stellanova's drug pipeline targets cancer-associated fibroblasts that spur tumors, which has shown unprecedented anti-tumor activity in multiple resistant cancer models. The company was founded by Rosa F. Hwang, Harold Levy, and Ronald A. DePinho, and the CEO is Emmanuelle Schuler. | Health Technology |
